¹**TITLE:** The dynamic impact of location and resection on the glioma CSF proteome.

2 **AUTHORS:** Cecile Riviere-Cazaux¹, Christopher J. Graser²⁻⁴, Arthur E. Warrington^{1,5}, Matthew 3 D. Hoplin¹, Katherine M. Andersen¹, Noor Malik¹, Elizabeth A. Palmer¹, Lucas P. Carlstrom^{1,6}, 4 Surendra Dasari⁷, Amanda Munoz-Casabella¹, Samar Ikram¹, Keyvan Ghadimi⁸, Benjamin T. 5 Himes⁸, Ignacio Jusue-Torres¹, Jann N. Sarkaria⁹, Fredric B. Meyer¹, Jamie J. Van Gompel¹, 6 Sani H. Kizilbash¹⁰, Ugur Sener⁵, Franziska Michor^{2-4,11-13}, Jian L. Campian¹⁰, Ian F. Parney¹, 7 Terry C. Burns^{1*}

⁸**AFFILIATIONS:**

9 Departments of ¹Neurological Surgery, ⁵Neurology, ⁷Quantitative Health Sciences, ⁹Radiation 10 Oncology, and ¹⁰ Medical Oncology, Mayo Clinic; Rochester, MN, USA

- 11 ²Department of Data Science, and ¹¹Center for Cancer Evolution, Dana-Farber Cancer Institute; 12 Boston, MA, USA
- ³Department of Biostatistics, Harvard T. H. Chan School of Public Health; Boston, MA, USA
- 14 ⁴Department of Stem Cell and Regenerative Biology, and 12 The Ludwig Center, Harvard
- 15 University; Cambridge, MA, USA
- ⁶Department of Neurological Surgery, The Ohio State University; Columbus, OH, USA
- ⁸ Department of Neurological Surgery, Montefiore/Albert Einstein College of Medicine; Bronx,
- 18 NY, USA
- 19 ¹²The Ludwig Center at Harvard; Boston, MA, USA
- 20 ¹³The Eli and Edythe L. Broad Institute of MIT and Harvard; Cambridge, MA, USA
- ²¹***CORRESPONDENCE:** Terry C. Burns, MD, PhD
- 22 Department of Neurosurgery Mayo Clinic

⁷**One Sentence Summary:** Glioma cerebrospinal fluid (CSF) accessed intra-operatively and 8 longitudinally via devices can reveal impacts of treatment and anatomical location.

⁹**ABSTRACT**

¹⁰While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid ¹¹(CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding 12 therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF 13 samples, including anatomical location and post-surgical changes, remains unknown. To that 14 end, pre- versus post-resection intracranial CSF samples were obtained at early (1-16 days; 15 n=20) or delayed (86-153 days; n=11) timepoints for patients with glioma. Paired lumbar-versus-16 intracranial glioma CSF samples were also obtained (n=14). Using aptamer-based proteomics, 17 we identify significant differences in the CSF proteome between lumbar, subarachnoid, and 18 ventricular CSF. Our analysis of serial intracranial CSF samples suggests the early potential for ¹⁹disease monitoring and evaluation of pharmacodynamic impact of targeted therapies. 20 Importantly, we found that resection had a significant, evolving longitudinal impact on the CSF 21 proteome. Proteomic data are provided with individual clinical annotations as a resource for the 22 field.

¹**INTRODUCTION**

Gliomas are primary brain tumors that inevitably recur despite maximal safe surgical resection and aggressive chemoradiation (*1*). No FDA-approved drug has improved survival for the most common of these tumors, glioblastoma (GBM), since temozolomide (TMZ) in 2005 (*2*). MRIs are standard-of-care for disease monitoring, but remain subject to confounders such as pseudoprogression (*3-7*). Although new techniques are emerging for measuring tumor burden and correlation to glioma biology (*8*), standard MRI sequences do not provide data regarding 8 the biological impacts of treatment. Liquid biopsies may serve as a source of monitoring and pharmacodynamic biomarkers (*9-12*). However, the blood-brain barrier limits passage of CNS-derived analytes (*13*), including glioma biomarkers (*8, 14-18*). In contrast, cerebrospinal fluid (CSF) is a proximal fluid that is an abundant biomarker source for brain tumors(*19-21*).

12 We and others have evaluated CSF for candidate brain tumor biomarkers such as cell-¹³free DNA (*11, 22-26*), and 2-hydroxyglutarate for IDH-mutant gliomas (*27-30*). The glioma CSF 14 proteome remains relatively underexplored, particularly for longitudinal monitoring of the impact 15 of standard-of-care or experimental therapies (31). Since CSF is typically protein-deficient, ¹⁶signal to noise for assessing disease burden and biological impacts of therapy may be superior 17 to plasma. A small number of studies have evaluated the glioma CSF proteome (32-36), most 18 often at a single timepoint. However, prior work has described a significant difference between ¹⁹the lumbar and intracranial CSF proteome(*37*) that could impact biomarker identification. 20 Indeed, optimal sensitivity for disease monitoring is obtained from biofluids in contact to tissue ²¹(*38, 39*) that can be obtained at the time of surgery or longitudinally via CSF access devices.

22 Toward our goal of establishing an early understanding of variables impacting the 23 Iongitudinal glioma CSF proteome that would be of relevance for longitudinal disease 24 monitoring, we performed aptamer-based proteomic analyses utilizing the Somalogic platform ²⁵(*40, 41*). Of multiple variables that could be evaluated, the impact of anatomical location and of

 \sim 3

1 resection were prioritized given their relevance to serial CSF acquisition, namely 1) longitudinal 2 CSF may be sampled from different anatomical locations prior to versus after resection, such as 3 the subarachnoid space upon dural opening and the resection cavity after resection, and 2) ⁴most patients with gliomas undergo glioma resection as part of standard-of-care treatment, the ⁵longitudinal impacts of which may be relevant for comparison to subsequently administered 6 systemic therapies.

⁷To answer these questions, 146 CSF samples from 74 patients, 71 of whom had grade ⁸2-4 astrocytomas or grade 2-3 oligodendrogliomas, were obtained, spanning different CSF ⁹compartments at multiple timepoints, including prior to and after resection. These data include ¹⁰1) intracranial samples from the subarachnoid space or ventricular system, including both 11 primary or recurrent gliomas, 2) paired lumbar and intracranial samples from patients with low 12 and high-grade gliomas, and 3) longitudinal glioma CSF from CSF access devices, such as ¹³Ommaya reservoirs (NCT04692337) (*27*), to evaluate the impact of resection and targeted 14 drugs. We found a significant impact of anatomical location of acquisition on the CSF proteome 15 of gliomas, in addition to a dynamic, evolving, and persistent impact of resection months after 16 surgery. Moreover, the glioma CSF proteome was highly enriched for plasma-derived proteins, 17 suggestive of the impact of blood-brain barrier disruption. All CSF proteomic data and sample 18 annotations are available for each patient included in this study to enable the neuro-oncology 19 community to query these patients' data for biomarker and biology discovery and validation.

²⁰**RESULTS**

²¹*Impact of anatomical location on the CSF proteome*

22 **Intracranial CSF can be obtained from multiple intracranial locations, including the** 23 ventricular system and subarachnoid space. To determine the proteomic impact of intracranial 24 sampling location, we compared CSF from the ventricular system versus subarachnoid space in 25 our most well-powered cohort, patients with GBMs, by performing separate Mann-Whitney U

1 tests for all proteins in our panel while using the Benjamini-Hochberg method to correct for 2 multiple hypothesis testing. We found that 1,033 aptamers had a higher signal in subarachnoid ³CSF, while 35 had elevated signals in ventricular CSF (FC>1.5, adjusted p-value<0.05, **Figure** ⁴**1Ai; Table 1**; full list in **Supplementary Table 1**). Of note, CAPSL was one of the most 5 significant ventricular-associated proteins, consistent with its known predominance in ⁶ependymal cells in the ventricle(*42*). Functional protein network analysis suggested enrichment 7 for metabolism-associated pathways in the subarachnoid GBM CSF samples, while ventricular ⁸CSF samples were enriched for developmental and immune processes (**Supplementary Table** ⁹**2).** To evaluate the reproducibility of this subarachnoid versus ventricular signature, the first 10 10 ventricular and 13 subarachnoid GBM CSF samples were allocated to a discovery cohort, with 11 the remainder of the samples ($n=10/11$) utilized for validation. Nearly identical overlap of the 12 subarachnoid CSF proteome was seen between the discovery and validation cohorts ¹³(FDR=0.000; **Figure 1Aii**), with similar findings for discovery/validation analyses in the 14 ventricular CSF proteome (FDR=0.000; Figure 1Aiii), confirming highly reproducible differences 15 in these two locations.

¹⁶Having identified a proteomic impact from intracranial anatomic location, we 17 hypothesized that a significant difference would exist between lumbar versus intracranial CSF. ¹⁸To address this question, we recruited patients to undergo intra-operative lumbar CSF sampling ¹⁹under anesthesia prior to surgery for intracranial tumor resection, when safe to do so. Among 14 20 paired intra-operatively acquired lumbar and intracranial CSF samples, 1,613 aptamers had an 21 elevated signal in intracranial CSF, while 271 had an increased signal in lumbar CSF (FC>1.5, ²²adjusted p-value<0.05; **Figure 1Bi; Table 1;** full list in **Supplementary Table 3**). Intracranial 23 CSF was enriched for metabolism-related processes, while lumbar CSF was enriched for 24 neuronal development pathways (Supplementary Table 2), consistent with increased ²⁵abundance of SHH, a known craniocaudal patterning protein(*43*). Discovery and validation

analysis (n=7 consecutive patients per cohort) demonstrated a highly reproducible location-associated CSF proteome via enrichment analysis and hierarchical clustering (FDR=0.000; **Figure 1Bii-iii)**. Hierarchical clustering revealed separated paired lumbar and intracranial samples based on anatomical location (**Figure 1Biv)**. We additionally asked whether the lumbar 5 versus intracranial CSF signature was identifiable regardless of the site of intracranial CSF acquisition. Enrichment analyses of intracranial CSF samples based on location (ventricle, 7 subarachnoid, or resection cavity) versus lumbar CSF revealed that the intracranial CSF 8 proteomes were positively enriched for each other when compared to lumbar CSF (FDR=0.000 for most comparisons; **Figure 1Bv**), regardless of intracranial location. In sum, the intracranial CSF proteome across all sites of acquisition was distinct from the lumbar proteome.

¹¹*Longitudinal impacts of resection on the CSF proteome*

12 **During the patient's disease course, the largest decrease in disease burden typically** 13 occurs via surgical resection. To determine the impact of surgical resection on the CSF 14 proteome, paired pre- and post-resection intracranial CSF samples were acquired for twenty 15 patients early in the patient's post-operative course (median=10.5 days, range=1-35). Ranked 16 fold-change lists were created to compare each patient's pre-resection to their post-resection 17 sample, revealing proteomic similarities in the pre-versus-post-resection signature across 18 patients (**Figure 2Ai).** Notably, this consistent proteomic signature could be observed even in 19 patients where post-resection CSF was obtained 3-5 weeks after resection as compared to 20 within the first few days after surgery. To evaluate the reproducibility of these findings, the first 21 and second 10 consecutive paired samples were utilized as discovery/validation cohorts, 22 revealing strong reproducibility (FDR=0.000; Figure 2Aii and Supplementary Figure 1A). ²³Given the impact of anatomical location (**Figure 1**), we also asked if the impact of resection 24 could be observed independent of whether pre-resection CSF was obtained from the ventricular 25 system (n=11) or subarachnoid space (n=7); two samples were excluded from analysis as the

1 site of origin was unknown in one patient and another originated from a resection cavity. When 2 compared to each patient's post-resection CSF, ventricular and subarachnoid pre-resection ³CSF samples were enriched for one another, demonstrating a conserved impact of resection on ⁴the CSF proteome regardless of site of origin (FDR=0.000; **Supplementary Figure 1Bi-ii**). The 5 same was also found when samples were divided based on primary $(n=14)$ versus recurrence ⁶(n=6) status (FDR=0.000; **Supplementary Figure 1Ci-ii**).

7 Wilcoxon rank-sum tests with Benjamini-Hochberg correction comparing the pre- versus 8 post-resection samples demonstrated that the signal for 1,872 aptamers was significantly higher ⁹for CSF prior to resection, while the signal increased for 326 aptamers early after resection ¹⁰(adjusted p<0.05; FC>1.5); **Figure 2Aiii; Table 1**; full list in **Supplementary Table 4).** 11 Functional protein network analysis of the top 200 of the 1,872 pre-resection aptamers revealed 12 enriched gene ontology (GO) biological process terms for metabolism-related pathways, 13 including small molecule metabolic processes (FDR= $2.36x10^{-22}$) and fatty acid beta-oxidation 14 (1.26x10⁻⁶) (**Figure 2Aiv)**. GO networks enriched in the 326 post-resection proteins included 15 immune responses (1.69x10⁻²¹), extracellular matrix reorganization (1.36x10⁻¹⁹), and response 16 to wounding (1.43x10⁻¹⁰), consistent with recent injury from surgical resection (**Figure 2Aiv)**.

¹⁷We recently demonstrated that the extracellular glioma metabolome is enriched for 18 plasma-associated metabolites, consistent with relative blood-brain barrier (BBB) disruption in 19 contrast-enhancing regions(*44*). As resection should decrease the abundance of glioma-20 associated proteins, some of which could be due to BBB disruption, we asked whether resection 21 could alter the relative enrichment of the CSF proteome for plasma-derived proteins. To do so, 22 we compared the pre-versus-early post-resection proteome to the ranked list of plasma-derived 23 proteins, generated from n=7 paired bloody versus clean CSF samples (**Supplementary Table** ²⁴**5)**. As expected, plasma-derived proteins were enriched for blood coagulation and immune ²⁵system-related processes, as well as cellular organization processes (**Supplementary Table 2).**

z₇

Early post-resection CSF is often more visibly contaminated than pre-resection CSF (**Supplementary Data**, annotations) due to post-surgical debris from recent tissue disruption. Nevertheless, plasma-associated aptamers were strongly enriched in glioma CSF at the time of maximal tumor burden when compared to early post-resection CSF (FDR=0.000; **Supplementary Figure 1Di)**, aligning with our recent findings in the glioma extracellular metabolome wherein blood-brain barrier portions of the tumor were enriched for plasma-derived 7 metabolites(44). This finding suggests that certain proteins in the CSF glioma proteome may be impacted by plasma-derived proteins that cross the tumor-disrupted BBB.

⁹Radiation with concurrent TMZ is standard-of-care after maximal safe resection for most ¹⁰patients with high-grade gliomas(*2*). We initially sought to characterize the impact of 11 chemoradiation on the CSF proteome after resection in patients with primary gliomas. ¹²Evaluation of 8 patients' pre-versus-post-chemoradiation CSF samples seemed to indicate a 13 proteomic difference between samples obtained prior to versus after radiation. However, paired 14 samples from one patient who did not receive chemoradiation revealed nearly identical 15 proteomic changes during this timeframe (**Supplementary Figure 2A)**. We therefore ¹⁶hypothesized that the CSF proteomic changes occurring between these early (<35 day) versus 17 late (>70 day) timepoints were more strongly attributable to the ongoing evolution of dynamic 18 post-operative changes, than chemoradiation (**Figure 2Bi)**. Of note, evaluation of early and 19 delayed timepoints was limited to patients with primary gliomas to minimize heterogeneity that 20 could be induced from various times since prior resection and/or systemic treatments.

21 As with the pre- versus early post-resection analyses, the first five and second four 22 patients were split into discovery and validation cohorts, respectively. Enrichment analysis 23 demonstrated a reproducible impact of delayed post-resection changes on the CSF proteome 24 as compared to the early post-resection timepoint (FDR=0.000; Figure 2Bii; Supplementary ²⁵**Figure 3B)**. An elevated signal was detected for 268 aptamers in the early post-resection

¹setting while 443 aptamers had an increased signal at the delayed timepoint (**Figure 2Biii;** ²**Table 1;** full list in **Supplementary Table 6).** Pathways related to cellular component 3 organization (FDR=4.82x10⁻⁶), organelle organization (4.51x10⁻⁵), and immune responses (1.40x10-4 ⁴) were more abundant in the early post-resection setting (**Figure 2Biv)**. At the delayed 5 timepoint, GO processes were enriched for neuronal/synaptic related pathways, including axon 6 development (1.13x10⁻³⁴), regulation of synapse assembly (1.93x10⁻¹⁴), and neuron recognition (2.90x10-8 ⁷) (**Figure 2Biv)**. Moreover, enrichment for plasma-derived proteins decreased by the ⁸delayed post-resection timepoint (**Supplementary Figure 2C**). Overall, these data suggested 9 an increased abundance of neuronal-associated proteins as post-resection changes evolve over 10 time.

11 Having compared pre-resection to early post-resection CSF, we then asked how the former would compare to the delayed post-resection timepoint. Comparing the 11 paired pre-resection versus delayed post-resection CSF samples resulted in similar findings (**Figure 2C)** from the pre-resection versus early post-resection comparison (**Figure 2A; Supplementary Table 7)**. These findings included a highly reproducible signature across discovery/validation cohorts (FDR=0.000; **Figure 2Cii; Supplementary Figure 3A)** and GO processes enriched for metabolism-associated pathways prior to resection and for immune/stress responses at the 18 delayed post-resection point (**Figure 2Ciii-iv**). Likewise, pre-resection CSF was more strongly enriched for plasma-derived proteins than the delayed post-resection timepoint (FDR=0.000; **Supplementary Figure 3B**). In sum, the impacts of resection could be identified in the CSF 21 proteome at both early and delayed timepoints, although neuronal-associated proteins became 22 more abundant with more time since resection.

²³*Evolution of post-resection CSF proteomic changes*

²⁴After comparing two of the three timepoints to one another, we then sought to integrate 25 these findings to evaluate the dynamic evolution of the CSF proteome. To do so, we identified

1 proteins that were more abundant at one timepoint as compared to both of the other timepoints (**Figure 3Ai; Supplementary Table 8**). These analyses identified a subset of proteins that (i) were elevated pre-resection and remained low post-resection (row 1 in **Figure 3Ai**; example: fibroblast growth factor 1, **Figure 3Bi**), (iii) increased transiently in the early post-resection setting (row 2; example: histone H2B Type 3-B, H2BU1, **Figure 3Bii**), (iii) increased early post-resection and remained elevated by the delayed post-resection timepoint, and (iv) increased most significantly in a delayed fashion post-resection (row 3; example, growth differentiation factor-15 (GDF-15), **Figure 3Biii**) (**Supplementary Table 8**). Additionally, evaluation of the top 10 plasma-associated proteins demonstrated decreased abundance over time (**Figure 3Aii**), 10 consistent with decreasing enrichment for the plasma-associated signature from pre-resection 11 to delayed post-resection CSF. Distinct differences were noted in the functional protein network enrichments at each timepoint. Namely, pre-resection proteins were enriched for metabolism-13 related processes and the early and delayed post-resection for stimuli response/immune 14 processes pathways (**Supplementary Table 2**).

15 Moreover, we also investigated whether proteins that increased over time after resection would remain elevated at the time of resection for recurrent glioma. To do so, we compared the 17 unpaired proteome of primary (n=31) versus recurrent (n=21) GBM, which identified 18 aptamers with significantly increased signal in the recurrent subgroup (FC>1.5, adjusted p-value<0.05) (**Table 1**; full list in **Supplementary Table 9**). Enrichment analysis revealed that 20 proteins elevated at the delayed post-resection timepoints (including its overlap with the early 21 post-resection proteins; n=150 aptamers) were enriched in the recurrent GBM CSF proteome when compared to primary GBMs (FDR=0.000; **Figure 3Ci**). Indeed, chitotriosidase-1 (CHIT1) was the protein that most significantly increased after resection (**Figure 3Ci)** and was the second most abundant protein in recurrent GBM when compared to primary tumors (**Figure 3Cii**). Although there was a low number of significantly differentially enriched proteins by

recurrence after p-value adjustment for multiple hypothesis testing, the significant proteomic enrichment for the post-resection signature suggests that its inflammatory components may still be detectable by the time of recurrence. In sum, the CSF proteome of gliomas dynamically evolves over time with resection.

⁵*The dynamic CSF proteome during therapy*

⁶Beyond imaging, few methods exist for monitoring glioma disease burden. We ⁷hypothesized that proteins decreasing with glioma resection could plausibly serve as an initial 8 protein set from which to identify candidate monitoring biomarkers. To assess the pilot feasibility ⁹of this approach, we evaluated the relative abundance of the top 25% of proteins decreasing ¹⁰with resection (**Figure 1A)** in three patients with grade 4 gliomas who exemplified divergent 11 disease courses over time. Patient 24, a female in her 50s, progressed through multiple 12 treatments at recurrence after resection of a recurrent GBM (**Figure 4A**). Patient 46, a female in 13 her 40s, had stable disease burden after resection and chemoradiation of an IDH-mutant grade ¹⁴4 astrocytoma (**Figure 4B)**. Patient 98, a male in his 40s, demonstrated pseudoprogression ¹⁵following resection and chemoradiation of an IDH-mutant grade 4 astrocytoma (**Figure 4C)**.

16 As an initial strategy, we reasoned that a monitoring biomarker should increase with true 17 disease progression. Of these top 25% proteins, BCAN emerged as the strongest candidate in 18 patient 24 based on its fold-change between progression timepoints, increasing by 3.58x and ¹⁹2.08x during progression through lomustine and bevacizumab, respectively (**Figure 4A)**. Most 20 of the other proteins elevated prior to resection did not increase reliably with disease 21 progression at each timepoint (Supplementary Figure 4Ai). Of note, VEGF-A had the greatest 22 increase in signal of all aptamers elevated with progression through bevacizumab (14.45x), 23 consistent with its relevance to blood-brain barrier disruption in HGGs(45, 46) in the setting of ²⁴failed radiographic response to this anti-VEGF-A antibody (**Figure 4A)**. GFAP was also 25 evaluated as a previously proposed biomarker of GBM($47-49$) and one of the top proteins that

the contract of the contract o
The contract of the contract o

increased with progression through bevacizumab (3.59x). However, unlike BCAN, both VEGF-A 2 and GFAP did not increase with progression through lomustine (1.03x and 0.63x, respectively). Epidermal growth factor receptor (EGFR) and growth-differentiation factor 15 (GDF-15), an indicator of p53 activity(*50*), were also evaluated for patient 24, since her GBM was EGFR-5 amplified and P53-wild type. EGFR and GDF-15 changed nominally during progression through lomustine, but increased by 2.83x and 1.70x, respectively, with progression through bevacizumab.

We then turned to evaluating BCAN, GFAP, and VEGF-A in patient 46, who had a radiographically stable IDH-mutant grade 4 astrocytoma after resection and chemoradiation. EGFR and GDF-15 were not evaluated due to their lack of relevance to her tumor genomics. In 11 patient 46, the BCAN signal decreased by 0.61x by the end of adjuvant temozolomide at POD334 (**Figure 4B),** consistent with decreasing D-2-hydroxyglutarate (D-2-HG), an 13 oncometabolite of IDH-mutant gliomas. GFAP increased by 1.39x with resection and decreased by 0.96x from pre-resection after adjuvant temozolomide, while VEGF-A remained low since 15 baseline. All proteins, including those that decreased with resection (**Supplementary Figure 4Aii),** remained relatively unchanged thereafter, correlating with her stable imaging.

17 Finally, in patient 98 whose disease course was characterized by pseudoprogression, 18 signals for BCAN and GFAP decreased to 0.23x and 0.10x of baseline, respectively, by ¹⁹POD305 after standard-of-care chemoradiation with adjuvant temozolomide (**Figure 4C),** 20 correlating with decreasing D-2-HG. In contrast, VEGF-A increased by 12.67x between the 21 post-chemoradiation and intra-operative baseline sample, as did a number of other proteins 22 elevated prior to resection that either then stabilized or began decreasing (**Supplementary** ²³**Figure 4Aiii)**. Indeed, while BCAN, GFAP, and VEGF decreased with each subsequent CSF 24 sample, the volume of T1-gadolinium positive tumor increased over time, until it began to 25 decrease by POD552, likely indicative of pseudoprogression.

1 Additionally, we also sought to test the preliminary feasibility of detecting 2 pharmacodynamic signals in CSF during systemic treatment. Protein network enrichment ³analysis of patient 24's CSF proteome during progression through CCNU between POD26 and 4 75 revealed similar neuronal-related enrichment pathways to the early versus delayed post-5 resection signature, consistent with a signature of resolving post-surgical changes between ⁶those timepoints and suggesting minimal pharmacodynamic impact of CCNU **(Supplementary** ⁷**Figure 4B-4Ci)**. In contrast, numerous aptamers increased during progression through 8 bevacizumab between POD75 and 118, including VEGF-A (14.45x), and its isoforms, VEGF165 ⁹and VEGF121 (**Figure 4Di)**. GO terms for progression through bevacizumab included mRNA 10 metabolic processes (5.00x10⁻³), response to organic substance (7.50x10⁻³), and regulation of 11 mRNA splicing $(8.40x10^{-3})$. Increases in these proteins between POD75 and 118 contrasted 12 their decrease in other patients over time after surgery (**Supplementary Figure 4Cii**), 13 suggesting a distinct PD impact of bevacizumab in CSF.

14 In another patient (Patient 79), CSF samples were obtained immediately prior to and 7 15 days after receiving pembrolizumab for a primary GBM with a hypermutant phenotype (POD28-¹⁶36). Observations included increased abundance of diverse interleukins, as well as lymphocyte 17 activation gene-3 (LAG-3), which is associated with T cell activation and serves as an alternate ¹⁸immune checkpoint to PD1(*51*), as blocked by pembrolizumab (**Figure 4Dii).** STRING analysis 19 demonstrated increased immune system processes (FDR=2.91x10 \degree) and cell killing pathways 20 $(6.40x10^{-3})$. Again, the increases in these proteins differed from their longitudinal time course in 21 other patients (**Supplementary Figure 4Ciii**), potentially indicative of a pharmacodynamic 22 impact of pembrolizumab.

23 Overall, these data suggest that the CSF proteome may reflect biological changes 24 occurring during disease evolution and therapy. Further work will be needed to evaluate the 25 reproducibility of such changes across patients and to determine the performance of other

ta di kacamatan ing Kabupatèn Kabupatèn Ing Kabupatèn Ing Kabupatèn Ing Kabupatèn Ing Kabupatèn Ing Kabupatèn
Kabupatèn

¹alternatives, such as individualized protein signatures based on each patient's baseline 2 proteome, for disease monitoring.

³**DISCUSSION**

⁴Toward our goal of understanding variables impacting the longitudinal glioma CSF 5 proteome, namely anatomical location and resection, we sampled intracranial or lumbar CSF at ⁶resection, in clinic, and/or longitudinally via CSF access devices in 74 patients comprising a 7 total of 146 samples, 71 of whom had grade 2-4 astrocytomas or grade 2-3 oligodendrogliomas. ⁸Our results demonstrate (1) a substantial impact of anatomical location on the glioma CSF 9 proteome, namely between subarachnoid versus ventricular CSF that may have implications for 10 Iongitudinal CSF acquisition wherein post-operative samples are often obtained from CSF in 11 continuity with the ventricle, (2) resection-induced changes in the intracranial glioma CSF 12 proteome that evolve over time, (3) enrichment for plasma-associated proteins prior to resection 13 that decreases temporally after resection, and (4) feasibility of longitudinal CSF acquisition for 14 analysis of preliminary pharmacodynamic changes in the intracranial CSF proteome. Although 15 many questions remain unanswered, our available data to date suggest that the intracranial ¹⁶glioma CSF proteome provides an abundant and evolving source of candidate biomarkers to 17 Iongitudinally discern the impact of resection and systemic treatments. All data are provided as 18 a resource for the neuro-oncology community to foster efforts to communally answer these 19 remaining questions and identify glioma biology via CSF proteomics.

While tissue is rarely accessible after therapy for treatment response assessment(*52*), 21 CSF can be sampled at multiple timepoints. We identify a conserved impact of resection on the glioma CSF proteome that is consistent with a tissue injury-induced inflammatory milieu(*53, 54*), and which persists in the months after surgery (**Figure 2-3).** Increased enrichment for neuronal-associated pathways between the early (<1 month) to delayed post-resection timepoint (2-5 25 months) suggest the ability to recover the brain CSF proteome after resection. This observation

could be due to decreased tumor burden with resection and chemoradiation. Additionally, decreasing enrichment for plasma-associated proteins over time may contribute to this finding(*55*), as non-plasma-associated CSF proteins in our paired bloody-versus-clean samples shared similar functional pathways related to cell adhesion and system/neuron development, albeit to less significant levels (**Supplementary Table 2)**. Additional longitudinal CSF samples from patients with low-grade gliomas, as with patient 212 (**Figure 2**), not undergoing any 7 therapy after resection will be utilized to isolate evolving post-resection changes from those induced by chemoradiation, other therapies, and disease recurrence. Although far more uncommon, non-treated, post-resection samples from patients with HGGs would also be of use 10 since the difference in the tumor microenvironment between LGGs and HGGs could plausibly 11 impact these evolving changes.

12 Moreover, the pre-resection CSF proteome was highly enriched for plasma-derived 13 proteins which decreased overtime after resection. While decreased plasma-derived enrichment 14 between early and delayed post-resection samples may be attributable to clearing of surgical 15 products, there was visibly increased contamination early after resection in longitudinal CSF 16 samples as compared to baseline pre-resection samples, where plasma-derived protein 17 enrichment was the highest. A prior CSF proteomic study found that abundance of albumin, a 18 plasma-derived protein, correlated with the number of differentially abundant CSF proteins(33). ¹⁹Our prior findings via microdialysis suggest that the tumor microenvironment is more enriched 20 for plasma-derived metabolites in the BBB disrupted as compared to BBB intact portions of the 21 tumor(44). As such, it is possible that tumor-associated blood-brain barrier disruption may 22 contribute to a portion of the glioma proteome. Indeed, clean intracranial CSF samples $(n=6)$ 23 were significantly more enriched for plasma-associated proteins than their paired lumbar 24 counterparts (**Supplementary Figure 1E**), consistent with the tumor as a source of plasma-25 associated proteins. The impact of BBB disruption could in part contribute to the large number

the contract of the contract o
The contract of the contract o

of proteins that were more abundant prior to resection due to tumor-induced BBB disruption, as compared to immediately post-resection (1,872 versus 326 proteins, respectively; **Figure 2A**). Whether plasma-derived protein enrichment has any impact on glioma growth and proliferation remains to be determined. However, serum is a routine component of cell culture media(*56*). Future studies may seek to evaluate whether blood-derived mitogens crossing a disrupted BBB could be as protumorigenic for the human glioma, *in situ*, as it is for *in vitro* cell cultures.

⁷Our findings suggest that the anatomical site of CSF origin, including lumbar or 8 subarachnoid versus ventricular CSF intracranially, profoundly impacts the CSF proteome. ⁹Previous work demonstrated a significant difference in the composition of paired intracranial 10 versus lumbar CSF in patients with NPH(37). To our knowledge, similar findings have not 11 previously been demonstrated for patients with gliomas. Cranial CSF should presumably afford ¹²a more abundant source of glioma-associated proteins due to tumor proximity(*11, 57*). Indeed, 13 our data in paired lumbar and intracranial glioma CSF samples demonstrate more differentially ¹⁴abundant proteins in intracranial CSF than lumbar CSF (**Figure 1B),** although this proximity ¹⁵may also increase the abundance of brain-associated proteins. Of note, of these 1,613 16 aptamers with higher signal in intracranial than lumbar CSF, 1,143 decreased with resection ¹⁷(70.9%; **Supplementary Table 10**), some of which could plausibly be associated with gliomas, 18 including its microenvironment and BBB disruption.

19 **Differences in the subarachnoid versus ventricular CSF should also be considered for** 20 Iongitudinal evaluation of samples due to changes in tumor contact, diffusion distance into CSF, 21 and continuity with the ventricular system that could impact protein abundance. However, this is 22 likely to depend on the protein under evaluation. For example, of 1,872 aptamers with a higher 23 signal prior to resection as compared to early post-resection, 696 (37.2.%) were also associated 24 with the subarachnoid GBM CSF, but 1,168 (62.4%) were not significantly different between 25 ventricular versus subarachnoid GBM CSF (**Supplementary Table 10**). Of note, the ventricular

1 system is frequently reached intra-operatively later than the subarachnoid CSF, after surgical 2 tissue disruption has occurred that could increase sample bloodiness. As such, we originally ³anticipated that ventricular CSF would be more enriched for plasma-associated proteins than ⁴subarachnoid CSF. However, we noted greater enrichment of subarachnoid GBM CSF for ⁵plasma-associated proteins when compared to ventricular CSF (**Supplementary Figure 1F)**. ⁶Subarachnoid CSF is more often sampled when there is greater tumor burden present (often 7 prior to resection). As many proteins elevated prior to glioma resection are plasma-associated, a 8 potential hypothesis may be that its enrichment for plasma-associated proteins originates from ⁹greater tumor burden present during sampling, although this remains to be proven.

10 Despite such need for careful consideration of potential co-variates, our data suggest the 11 feasibility of discerning unique biological impacts of tumor-targeted therapy within a patient's ¹²CSF by serially sampling same location prior to and after therapy in individual patients (**Figure** ¹³**4D)**. Pembrolizumab increased the abundance of numerous cytokines/chemokines, as expected ¹⁴from an immunotherapy--especially in a hypermutant tumor(*58*). Interestingly, LAG-3, an 15 immune checkpoint inhibitor, was more abundant in CSF after blockade of the PD-L1 16 checkpoint inhibitor pembrolizumab. Combined blockade of PD-L1 and LAG-3 improved survival 17 in preclinical models and is currently under clinical trial evaluation for GBM, illustrating the 18 potential of identifying emergent mechanisms of resistance via CSF analysis on a patient-by-19 patient basis(*59*). Of note, while LAG-3 did not increase with resection when compared to pre-20 resection, it did increase by the delayed post-resection timepoint as compared to early pre-21 resection. As such, the temporal changes occurring in CSF after resection, independent of 22 these targeted therapies, should be considered in parallel when evaluating PD impact. In 23 contrast, progression through CCNU and bevacizumab in one patient yielded two distinct CSF 24 proteomic signatures, perhaps illustrating the dynamic nature of tumor responses to therapeutic 25 stress. The >20x upregulation of VEGF-A as the top upregulated protein following bevacizumab

may illustrate the tumor ecosystem's capacity to resist therapy with remarkable precision. Again, 2 parallel timepoints in patients with recurrent disease not undergoing treatment with CCNU or bevacizumab are likely needed to definitively attribute these changes to the therapies. Nevertheless, these data provide early signals on the potential of CSF for discerning PD impacts toward empirically guided individualized therapy. In sum, the data provided in this manuscript illustrate the potential utility of leveraging the dynamic CSF proteome longitudinally 7 in our collective efforts against glioma.

⁸**MATERIALS AND METHODS**

⁹*Patient recruitment, informed consent, and IRB approval*

10 Cerebrospinal fluid (CSF) samples were collected with informed consent via one or more 11 Institutional Review Board-approved protocols. Samples collected intra-operatively from the 12 surgical field were banked under our neuro-oncology biorepository protocol. Any patient 13 undergoing resection was eligible for enrollment into the biorepository protocol. Additionally, 14 Iongitudinal CSF sampling was enabled in most cases by an Ommaya reservoir implanted 15 under a research protocol for brain tumor biomarker access at the time of tumor resection ¹⁶(NCT04692337). For this initial study, patients with suspected or known low-grade or high-grade 17 gliomas were recruited. Moreover, some samples were accessed via a clinically-indicated 18 ventriculoperitoneal shunt or post-operative external ventricular drain under our CSF biomarkers 19 study (NCT04692324). The CSF biomarkers study was also utilized to obtain lumbar CSF from 20 lumbar punctures, either intra-operatively after anesthesia induction or in clinic.

²¹*Cerebrospinal fluid collection and processing*

22 Intra-operatively obtained samples were most often acquired from an exposed sulcus 23 after dural opening, a prior resection cavity, and/or once the ventricle was reached, when 24 applicable. Efforts were taken to minimize blood contamination of each sample. For patients

with an Ommaya reservoir, the catheter was placed in the resection cavity at the completion of 2 the case—most of which contacted the ventricle, except where annotated in the figures. Most Ommayas utilized had a 1.5 cm side with a flat bottom and side inlet connected to an antibiotic-impregnated ventricular catheter (Natus ® NT8501214; Codman ® Hakim Bacisteal Catheter, 5 NS5048). Ommayas were placed such that would be minimally visible while ensuring the catheter did not cross the incision line. For all CSF samples, CSF was centrifuged at 400xG for 7 10 minutes at 4°C and aliquoted for storage at -80°C, with collection and processing time noted
8 for each sample. Clinical information. including pathology. age. sex. tumor location. and other for each sample. Clinical information, including pathology, age, sex, tumor location, and other variables, was documented for each sample ("Annotations", **Supplementary Data**).

¹⁰*Aptamer-based proteomics*

11 De-identified CSF samples were sent for aptamer-based proteomics analysis on the ¹²Somalogic SomaScan® platform(*40*). This method utilizes protein-captured Slow Off-rate ¹³Modified Aptamers (SOMAmers ®) to sensitively and reproducibly (<5% coefficient of variance) 14 detect over 7,000 proteins in liquid specimens. Some of these single-stranded DNA-based ¹⁵SOMAmer reagents have been chemically modified and incorporated into nucleotide libraries for 16 selection and amplification via Systematic Evolution of Ligands by EXponential enrichment ¹⁷(SELEX)(*41*). Although originally utilized for human plasma, serum, and urine, this technology 18 is now being deployed in CSF(60).

19 **Details of this method have been more extensively detailed in prior publications(40).** 20 Briefly, 20 uL of CSF are diluted and incubated with SOMAmer reagent mixes including 21 streptavidin (SA)-coated beads. After the beads are washed, an NHS-biotin agent is utilized to 22 tag the proteins specifically bound by SOMAmer reagents. Ultraviolet light then cleaves the 23 linker within the SOMAmer reagent to release the SOMAmer complex and unbound reagents 24 into an anionic solution, causing any nonspecific interaction to dissociate and preventing 25 reformation. Beads are then used to separate the photocleavage eluate prior to incubation with

na matsay na katalog as na mga 1920 na mga 1930 na
Mga 1931 na mga 1932 na mg

¹a second set of SA-coated beads which bind biotin-labeled proteins and those complexed with 2 SOMAmers. Another washing step is utilized to remove non-specifically bound reagents. Finally, 3 protein-bound SOMAmer reagents are released via denaturation to quantify the reagents via ⁴hybridization to custom DNA microarrays based on a cyanine-3 signal in the reagent.

⁵*Data standardization and processing*

⁶The 96-well plate utilized by Somalogic includes control, quality (pooled), calibrator ⁷(pooled), and buffer (no protein) samples. Raw data obtained from hybridization undergo ⁸hybridization normalization. Hybridization normalization uses twelve control SOMAmer reagents ⁹that are added to the eluate prior to scanning the microarray, without exposure to proteins. ¹⁰Median signal normalization is then performed using pooled calibrator replicates to normalize for 11 within-run technical variation. Then, for each SOMAMer® reagent, a scaling factor is calculated 12 and performed, including 1) the plate scale (median ratio; to adjust for differences in signal 13 intensity between runs) and 2) the calibration scale (recalculated set of scale factor based on 14 calibrators; to adjust for SOMAmer reagent assay differences between runs). A scaling factor is 15 then applied to the microarray based on a scaling factor from the control signals. Adaptive 16 Normalization by Maximum Likelihood (ANML) normalization is then performed. Each ¹⁷SOMAmer reagent has a scale factor within a dilution bin (S1, S2, S3) that is calculated based 18 on sample values within two population standard deviations of the normal reference. This 19 process is then repeated until convergence to increase the likelihood that the RFU for a sample 20 is from the reference distribution.

21 Samples were sent across multiple batches. To evaluate for potential batch effects, a 22 small subset of samples was sent across multiple batches. Data were provided by Somalogic 23 for each step in their analysis pipeline. As another normalization technique, we had also ²⁴performed 1) Trimmed Mean of M-values normalization(*61*) (based on top and bottom 5%) and ²⁵2) median normalization based on the median value within a sample on Somalogic's

1 hybridization normalized data. To determine which data normalization strategy to utilize for our 2 analyses, we evaluated the correlation of our duplicate samples across batches to one another. ³Overall, ANML normalized data had the strongest correlation between batches for repeat 4 samples (R^2 = 0.94-0.97, 5 samples) and was utilized for all analyses hereon. Proteins flagged in 5 any batch were removed from downstream analyses, resulting in 7,011 analyzable aptamers ⁶compared to a starting point of 7,596 aptamers.

⁷*Enrichment analyses*

⁸To perform enrichment analyses, the ANML value for each aptamer was compared ⁹across samples. In order to compare paired samples for an individual patient, aptamers were 10 ranked based on fold-change (sample $1 /$ sample 2) resulting in a ranked list for each 11 comparison (e,g pre- versus post-resection). For group comparisons, the average ANML value 12 for each group was calculated and the fold change of each protein between groups determined 13 to generate the ranked list. For discovery and validation analyses, samples were split into half, ¹⁴with the first chronological half (based on patient number) in the discovery cohort and the 15 second half in the validation cohort. Discovery and validation were also performed based on 16 primary versus recurrent tumor status and subarachnoid versus ventricular pre-resection CSF, ¹⁷where applicable in the manuscript. Fold-change ranked lists were created for each discovery 18 and validation cohort. If a patient had multiple intra-operative CSF samples obtained, or if their ¹⁹CSF was run across multiple batches, the first CSF sample obtained was utilized under the ²⁰most realistic assumption that only one sample could be obtained in most surgeries. The only 21 exception was if the first sample was part of known bloody and clean pair of samples, in which 22 case the less contaminated sample was utilized.

23 To determine the statistical significance of the similarity between ranked lists, Gene Set ²⁴Enrichment Analysis® was repurposed for proteomics. Libraries for each comparison were 25 generated using the top 5% of proteins in the comparison based on the fold-change (350

proteins). The exception was the evaluation of early and delayed post-resection proteins in the recurrent versus primary GBM proteome, that were identified as described in *Volcano plots, heatmaps, and hierarchical clustering* below. The Ranked lists (.rnk) were then utilized to 4 determine where the proteins in each library fell on the ranked list. Ranked lists were based on fold-changes across comparisons of interest. The pre-rank function was utilized with classic enrichment statistic, mean-divided normalization, and 1000 permutations. Positive enrichment 7 indicated that the library's proteins fell toward the top of the list, suggesting an overlap in their upregulated proteomes. Negative enrichment indicated that the ranked proteome was similar to 9 the opposite end of the ranked list.

¹⁰*Volcano plots, heatmaps, and hierarchical clustering*

11 Volcano plots were generated based on results of non-parametric t-tests performed to 12 compare groups for each aptamer. First, normality of the overall data set was tested via 13 D'Agostino-Pearson test. As the data were not normally distributed for every aptamer, non-14 parametric testing was performed for all aptamers, including Wilcoxon Signed-rank tests for 15 paired data (pre-versus post-early or delayed resection; early versus delayed post-resection; 16 Iumbar-versus-intracranial) or the Mann-Whitney U tests for unpaired data (ventricular versus 17 subarachnoid GBM; primary versus recurrent GBM). Given the number of aptamers on the 18 panel, multiple hypothesis correction was performed using the Benjamini-Hochberg method.

19 For the heatmap in Figure 3A, the top 10 proteins were identified for each row from the 20 volcano plots generated in Figure 2 at FC>1.5 and adjusted p-value<0.05. To identify proteins 21 unique to one timepoint, we evaluated the proteins that were elevated in that timepoint when it 22 was compared to both of the other timepoints. For example, to identify pre-resection specific 23 proteins, we identified the significant proteins overlapping between the pre-resection versus 24 early-post-resection and pre-resection versus delayed post-resection volcano plots. To identify 25 proteins shared between two timepoints, but not the other, we evaluated the overlap between

1 those two timepoints as compared to the third timepoint. For examples, to identify proteins 2 shared between pre-resection and early post-resection samples, but not delayed post-resection ³CSF, we found the significant proteins overlapping between pre-resection versus delayed-post ⁴resection and early post-resection versus delayed-post-resection comparisons. The top 10 5 plasma-associated proteins based on the plasma-derived versus clean FC were plotted over 6 time in each longitudinal samples.

7 STRING.db was utilized to perform functional protein network enrichment analyses and 8 identify Gene Ontology (GO) processes by inputting up to the top 200 proteins for each protein 9 list based on fold-change, or in the case of Figure 3/Supplementary Table 8, the proteins that ¹⁰were identified for each timepoint. MetaboAnalyst 6.0 was utilized to perform hierarchical 11 clustering (Euclidean distance measure, with Ward's method for clustering). ANOVA or t-tests ¹²were utilized for hierarchical clustering. GraphPad PRISM 10.0.1 was utilized to generate 13 graphs.

¹**List of Supplementary Materials**

- ²Supplementary Figures S1: Enrichment analyses with paired pre-versus-early post-resection
- ³CSF samples from patients with gliomas.
- ⁴Supplementary Figure S2: Enrichment analyses in 9 paired early and delayed post-resection
- 5 CSF samples from patients with gliomas.
- ⁶Supplementary Figure S3: Enrichment analyses in the 11 paired pre-resection versus delayed
- 7 post-resection CSF samples from patients with gliomas.
- 8 Supplementary Figure S4: Evaluation of candidate monitoring and pharmacodynamic proteins in
9 Iongitudinal CSF samples. longitudinal CSF samples.
- 10 Supplementary Tables 1-10
- 11 Data File 1: all raw data

¹²**References**

- 13 1. M. Weller, W. Wick, K. Aldape, M. Brada, M. Berger, S. M. Pfister, R. Nishikawa, M.
14 Rosenthal, P. Y. Wen, R. Stupp, G. Reifenberger, Glioma. Nature Reviews Disease 14 Rosenthal, P. Y. Wen, R. Stupp, G. Reifenberger, Glioma. *Nature Reviews Disease Primers* 1, 15017 (2015). ¹⁵*Primers* **¹**, 15017 (2015).
- 16 2. R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K.
17 Selanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. 17 Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K.
18 Ludwin. T. Gorlia. A. Allgeier. D. Lacombe. J. G. Cairncross. E. Eisenhauer. R. O. 18 Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, R. O.
19 Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for glioblas 19 Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
20 Mengl J Med 352, 987-996 (2005). ²⁰*N Engl J Med* **³⁵²**, 987-996 (2005).
- 21 3. M. Law, S. Yang, H. Wang, J. S. Babb, G. Johnson, S. Cha, E. A. Knopp, D. Zagzag,
22 **Clioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imagi**n 22 Glioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imaging
23 Senald Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging. 23 and Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging.
24 American Journal of Neuroradiology 24, 1989-1998 (2003). ²⁴*American Journal of Neuroradiology* **²⁴**, 1989-1998 (2003).
- 25 4. J. D. Bernstock, S. E. Gary, N. Klinger, P. A. Valdes, W. Ibn Essayed, H. E. Olsen, G.
26 Chagoya, G. Elsayed, D. Yamashita, P. Schuss, F. A. Gessler, P. Paolo Peruzzi, A. K. 26 Chagoya, G. Elsayed, D. Yamashita, P. Schuss, F. A. Gessler, P. Paolo Peruzzi, A. K.
27 Sag, G. K. Friedman, Standard clinical approaches and emerging modalities for 27 Bag, G. K. Friedman, Standard clinical approaches and emerging modalities for
28 Gelioblastoma imaging. Neuro-Oncology Advances 4, (2022). 28 glioblastoma imaging. *Neuro-Oncology Advances* 4, (2022).
29 5. P. Y. Wen, M. v. d. Bent, G. Youssef, T. F. Cloughesy, B. M.
- 29 5. P. Y. Wen, M. v. d. Bent, G. Youssef, T. F. Cloughesy, B. M. Ellingson, M. Weller, E.
30 Galanis, D. P. Barboriak, J. d. Groot, M. R. Gilbert, R. Huang, A. B. Lassman, M. Mel 30 Galanis, D. P. Barboriak, J. d. Groot, M. R. Gilbert, R. Huang, A. B. Lassman, M. Mehta, 31 (a. 1914)
31 A. M. Molinaro, M. Preusser, R. Rahman, L. K. Shankar, R. Stupp, J. E. Villanueva-31 A. M. Molinaro, M. Preusser, R. Rahman, L. K. Shankar, R. Stupp, J. E. Villanueva-
32 Meyer, W. Wick, D. R. Macdonald, D. A. Reardon, M. A. Vogelbaum, S. M. Chang, 32 Meyer, W. Wick, D. R. Macdonald, D. A. Reardon, M. A. Vogelbaum, S. M. Chang,
33 RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for Hig 33 RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High-
34 and Low-Grade Gliomas in Adults. Journal of Clinical Oncology 41, 5187-5199 (2023). ³⁴and Low-Grade Gliomas in Adults. *Journal of Clinical Oncology* **⁴¹**, 5187-5199 (2023).

1 6. R. Y. Huang, M. R. Neagu, D. A. Reardon, P. Y. Wen, Pitfalls in the neuroimaging of qlioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting 2 glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting
3 illusive disease, defining response. *Front Neurol* 6, 33 (2015). ³illusive disease, defining response. *Front Neurol* **⁶**, 33 (2015). 4 7. M. C. de Wit, H. G. de Bruin, W. Eijkenboom, P. A. Sillevis Smitt, M. J. van den Bent,
5 mmediate post-radiotherapy changes in malignant glioma can mimic tumor progressi 5 Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
6 Meurology 63, 535-537 (2004). ⁶*Neurology* **⁶³**, 535-537 (2004). 7 8. M. Touat, A. Duran-Peña, A. Alentorn, L. Lacroix, C. Massard, A. Idbaih, Emerging
8 circulating biomarkers in glioblastoma: promises and challenges. Expert Rev Mol D. ⁸circulating biomarkers in glioblastoma: promises and challenges. *Expert Rev Mol Diagn* ⁹**15**, 1311-1323 (2015). 10 9. R. Soffietti, C. Bettegowda, I. K. Mellinghoff, K. E. Warren, M. S. Ahluwalia, J. F. De
11 **Charling Carling, M. R. Gilbert, K. A. Jaeckle, E. Le Rhun, R. Rudà, J. Seoane, N.** 11 Groot, E. Galanis, M. R. Gilbert, K. A. Jaeckle, E. Le Rhun, R. Rudà, J. Seoane, N.
12 Thon, Y. Umemura, M. Weller, M. J. van den Bent, M. A. Vogelbaum, S. M. Chang, 12 Thon, Y. Umemura, M. Weller, M. J. van den Bent, M. A. Vogelbaum, S. M. Chang, P. Y.
13 Wen, Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. 13 Wen, Liquid biopsy in gliomas: A RANO review and proposals for clinical applications.
14 Meuro-Oncology 24, 855-871 (2022). ¹⁴*Neuro-Oncology* **²⁴**, 855-871 (2022). 15 10. S. J. Bagley, S. A. Nabavizadeh, J. J. Mays, J. E. Till, J. B. Ware, S. Levy, W.
16 Sarchiapone, J. Hussain, T. Prior, S. Guiry, Clinical utility of plasma cell-free D 16 Sarchiapone, J. Hussain, T. Prior, S. Guiry, Clinical utility of plasma cell-free DNA in
17 adult patients with newly diagnosed glioblastoma: a pilot prospective study. Clinical 17 adult patients with newly diagnosed glioblastoma: a pilot prospective study. *Clinical* **Cancer Research 26**, 397-407 (2020). ¹⁸*Cancer Research* **²⁶**, 397-407 (2020). 19 11. A. M. Miller, R. H. Shah, E. I. Pentsova, M. Pourmaleki, S. Briggs, N. Distefano, Y.
20 **19 20 18 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 20 19 2** 20 Zheng, A. Skakodub, S. A. Mehta, C. Campos, W.-Y. Hsieh, S. D. Selcuklu, L. Ling, F.
21 Meng, X. Jing, A. Samoila, T. A. Bale, D. W. Y. Tsui, C. Grommes, A. Viale, M. M. 21 Meng, X. Jing, A. Samoila, T. A. Bale, D. W. Y. Tsui, C. Grommes, A. Viale, M. M.
22 Souweidane, V. Tabar, C. W. Brennan, A. S. Reiner, M. Rosenblum, K. S. Panage 22 Souweidane, V. Tabar, C. W. Brennan, A. S. Reiner, M. Rosenblum, K. S. Panageas, L.
23 M. DeAngelis, R. J. Young, M. F. Berger, I. K. Mellinghoff, Tracking tumour evolution in 23 M. DeAngelis, R. J. Young, M. F. Berger, I. K. Mellinghoff, Tracking tumour evolution in
24 dioma through liquid biopsies of cerebrospinal fluid. Nature **565**, 654-658 (2019). 24 glioma through liquid biopsies of cerebrospinal fluid. *Nature* **565**, 654-658 (2019).
25 12. E. Le Rhun, J. Seoane, M. Salzet, R. Soffietti, M. Weller, Liquid biopsies for diagn 25 12. E. Le Rhun, J. Seoane, M. Salzet, R. Soffietti, M. Weller, Liquid biopsies for diagnosing
26 and monitoring primary tumors of the central nervous system. Cancer Lett 480, 24-28 26 and monitoring primary tumors of the central nervous system. *Cancer Lett* **480**, 24-28
27 (2020). 27 (2020).
28 13. J. F. De 28 13. J. F. Deeken, W. Löscher, The blood-brain barrier and cancer: transporters, treatment, 29 and Trojan horses. Clin Cancer Res 13, 1663-1674 (2007). ²⁹and Trojan horses. *Clin Cancer Res* **¹³**, 1663-1674 (2007). ³⁰14. J. Rincon-Torroella, H. Khela, A. Bettegowda, C. Bettegowda, Biomarkers and focused ³¹ultrasound: the future of liquid biopsy for brain tumor patients. *J Neurooncol* **¹⁵⁶**, 33-48 32 (2022).
33 15. Y. Meno 33 15. Y. Meng, C. B. Pople, S. Suppiah, M. Llinas, Y. Huang, A. Sahgal, J. Perry, J. Keith, B.
34 **Canadian, B. Hamani, Y. Amemiya, A. Seth, H. Leong, C. C. Heyn, I. Aubert, K.** Davidson, C. Hamani, Y. Amemiya, A. Seth, H. Leong, C. C. Heyn, I. Aubert, K.
35 Hynynen, N. Lipsman, MR-guided focused ultrasound liquid biopsy enriches circ 35 Hynynen, N. Lipsman, MR-guided focused ultrasound liquid biopsy enriches circulating
36 biomarkers in patients with brain tumors. Neuro Oncol 23, 1789-1797 (2021). ³⁶biomarkers in patients with brain tumors. *Neuro Oncol* **²³**, 1789-1797 (2021). 37 16. J. Yuan, L. Xu, C.-Y. Chien, Y. Yang, Y. Yue, S. Fadera, A. H. Stark, K. E. Schwetye, A.
38 **Mazeri, R. Desai, U. Athiraman, A. A. Chaudhuri, H. Chen, E. C. Leuthardt, First-in-**38 Nazeri, R. Desai, U. Athiraman, A. A. Chaudhuri, H. Chen, E. C. Leuthardt, First-in-39 human prospective trial of sonobiopsy in high-grade glioma patients using
40 heuronavigation-guided focused ultrasound. *npi Precision Oncology* 7, 92 40 neuronavigation-guided focused ultrasound. *npj Precision Oncology* **7**, 92 (2023).
41 17. C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartl 17. C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H.
42 Wang, B. Luber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L. 42 Wang, B. Luber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L.
43 Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M. 43 Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M.
44 Goggins, M. D. Hogarty, M. Holdhoff, S. M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G 44 Goggins, M. D. Hogarty, M. Holdhoff, S. M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G.
45 Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. Marie, G. J. Nett 45 Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. Marie, G. J. Netto, K.
46 S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, M. Shih I, S. 46 S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, M. Shih I, S.
47 M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T. T. Harkins, S. Veronese, T. L. 47 M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T. T. Harkins, S. Veronese, T. L.
48 Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, F 48 Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, P. J.
49 Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N. 49 Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N.
49 Fapadopoulos, L. A. Diaz, Jr., Detection of circulating tumor DNA in early- and late-50 Papadopoulos, L. A. Diaz, Jr., Detection of circulating tumor DNA in early- and late-
51 stage human malignancies. Sci Transl Med 6. 224ra224 (2014). ⁵¹stage human malignancies. *Sci Transl Med* **⁶**, 224ra224 (2014).

13. L. Zhu, G. Cheng, D. Ye, A. Nazeri, Y. Yue, W. Liu, X. Wang, G. P. Dunn, A. A. Petti, E.
2. C. Leuthardt, H. Chen, Focused Ultrasound-enabled Brain Tumor Liquid Biopsy. Sci Reg ²C. Leuthardt, H. Chen, Focused Ultrasound-enabled Brain Tumor Liquid Biopsy. *Sci Rep* ³**8**, 6553 (2018). 19. F. Xiao, S. Lv, Z. Zong, L. Wu, X. Tang, W. Kuang, P. Zhang, X. Li, J. Fu, M. Xiao, M.
5 Wu, L. Wu, X. Zhu, K. Huang, H. Guo, Cerebrospinal fluid biomarkers for brain tumor 5 Wu, L. Wu, X. Zhu, K. Huang, H. Guo, Cerebrospinal fluid biomarkers for brain tumor
6 detection: clinical roles and current progress. Am J Transl Res 12, 1379-1396 (2020). ⁶detection: clinical roles and current progress. *Am J Transl Res* **¹²**, 1379-1396 (2020). 7 20. L. Escudero, A. Llort, A. Arias, A. Diaz-Navarro, F. Martínez-Ricarte, C. Rubio-Perez, R.
8 Mayor, G. Caratù, E. Martínez-Sáez, É. Vázquez-Méndez, I. Lesende-Rodríguez, R. 8 Mayor, G. Caratù, E. Martínez-Sáez, É. Vázquez-Méndez, I. Lesende-Rodríguez, R.
9 Hladun, L. Gros, S. Ramón y Cajal, M. A. Poca, X. S. Puente, J. Sahuquillo, S. Galle 9 Hladun, L. Gros, S. Ramón y Cajal, M. A. Poca, X. S. Puente, J. Sahuquillo, S. Gallego,
10 J. Seoane, Circulating tumour DNA from the cerebrospinal fluid allows the 10 J. Seoane, Circulating tumour DNA from the cerebrospinal fluid allows the
11 characterisation and monitoring of medulloblastoma. Nature Communication 11 characterisation and monitoring of medulloblastoma. *Nature Communications* **11**, 5376
12 (2020). 12 (2020).
13 21. J. M. Kr 13 21. J. M. Kros, D. M. Mustafa, L. J. M. Dekker, P. A. E. Sillevis Smitt, T. M. Luider, P.-P.
14 Zheng, Circulating glioma biomarkers. Neuro-Oncology 17, 343-360 (2014). ¹⁴Zheng, Circulating glioma biomarkers. *Neuro-Oncology* **¹⁷**, 343-360 (2014). 15 22. A. P. Y. Liu, K. S. Smith, R. Kumar, L. Paul, L. Bihannic, T. Lin, K. K. Maass, K. W.
16 **Paitler, M. Chintagumpala, J. M. Su, E. Bouffet, M. J. Fisher, S. Gururangan, R. Co** 16 Pajtler, M. Chintagumpala, J. M. Su, E. Bouffet, M. J. Fisher, S. Gururangan, R. Cohn, T.
17 Hassall, J. R. Hansford, P. Klimo, Jr., F. A. Boop, C. F. Stewart, J. H. Harreld, T. E. 17 Hassall, J. R. Hansford, P. Klimo, Jr., F. A. Boop, C. F. Stewart, J. H. Harreld, T. E.
18 Merchant, R. G. Tatevossian, G. Neale, M. Lear, J. M. Klco, B. A. Orr, D. W. Ellison 18 Merchant, R. G. Tatevossian, G. Neale, M. Lear, J. M. Klco, B. A. Orr, D. W. Ellison, R.
19 J. Gilbertson, A. Onar-Thomas, A. Gajjar, G. W. Robinson, P. A. Northcott, Serial 19 J. Gilbertson, A. Onar-Thomas, A. Gajjar, G. W. Robinson, P. A. Northcott, Serial
20 sepessment of measurable residual disease in medulloblastoma liquid biopsies. C 20 assessment of measurable residual disease in medulloblastoma liquid biopsies. *Cancer* **Cell 39**, 1519-1530.e1514 (2021). ²¹*Cell* **³⁹**, 1519-1530.e1514 (2021). 22 23. C. Riviere-Cazaux, X. Dong, W. Mo, C. Dai, L. P. Carlstrom, A. Munoz-Casabella, R.
23 Kumar, K. Ghadimi, C. L. Nesvick, K. M. Andersen, M. D. Hoplin, N. Canaday, I. Jusu 23 Kumar, K. Ghadimi, C. L. Nesvick, K. M. Andersen, M. D. Hoplin, N. Canaday, I. Jusue-24 Torres, N. Malik, J. L. Campian, M. W. Ruff, J. H. Uhm, J. E. E. Passow, T. J. Kaufmann, 25 [10] D. M. Routman, S. H. Kizilbash, A. E. Warrington, R. B. Jenkins, P. Du, S. Jia, T. C. 25 C. M. Routman, S. H. Kizilbash, A. E. Warrington, R. B. Jenkins, P. Du, S. Jia, T. C.
26 **Burns, Longitudinal glioma monitoring** via cerebrospinal fluid cell-free DNA: one pational 26 Burns, Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA: one patient 27 at a time. medRxiv, 2024.2002.2021.24303164 (2024). 27 at a time. *medRxiv*, 2024.2002.2021.24303164 (2024).
28 24. A. E. McEwen, S. E. S. Leary, C. M. Lockwood, Beyonc 28 24. A. E. McEwen, S. E. S. Leary, C. M. Lockwood, Beyond the Blood: CSF-Derived cfDNA
29 for Diagnosis and Characterization of CNS Tumors. *Front Cell Dev Biol* 8, 45 (2020). ²⁹for Diagnosis and Characterization of CNS Tumors. *Front Cell Dev Biol* **⁸**, 45 (2020). 30 25. M. D. White, R. H. Klein, B. Shaw, A. Kim, M. Subramanian, J. L. Mora, A. Giobbie-
31 Hurder, D. Nagabhushan, A. Jain, M. Singh, B. M. Kuter, N. Nayyar, M. S. Bertalan, 31 Hurder, D. Nagabhushan, A. Jain, M. Singh, B. M. Kuter, N. Nayyar, M. S. Bertalan, J.
32 H. Stocking, S. C. Markson, M. Lastrapes, C. Alvarez-Breckenridge, D. P. Cahill, G. 32 H. Stocking, S. C. Markson, M. Lastrapes, C. Alvarez-Breckenridge, D. P. Cahill, G.
33 Gydush, J. Rhoades, D. Rotem, V. A. Adalsteinsson, M. Mahar, A. Kaplan, K. Oh, R 33 Gydush, J. Rhoades, D. Rotem, V. A. Adalsteinsson, M. Mahar, A. Kaplan, K. Oh, R. J.
34 Sullivan, E. Gerstner, S. L. Carter, P. K. Brastianos, Detection of Leptomeningeal 34 Sullivan, E. Gerstner, S. L. Carter, P. K. Brastianos, Detection of Leptomeningeal
35 Disease Using Cell-Free DNA From Cerebrospinal Fluid. JAMA Network Open 4, 35 Disease Using Cell-Free DNA From Cerebrospinal Fluid. *JAMA Network Open* 4,
36 e2120040-e2120040 (2021). 36 e2120040-e2120040 (2021).
37 26. R. Mair, F. Mouliere, Cell-free ³⁷26. R. Mair, F. Mouliere, Cell-free DNA technologies for the analysis of brain cancer. *British* ³⁸*Journal of Cancer* **¹²⁶**, 371-378 (2022). 39 27. C. Riviere-Cazaux, J. M. Lacey, L. P. Carlstrom, W. J. Laxen, A. Munoz-Casabella, M.
40 **D. Hoplin, S. Ikram, A. B. Zubair, K. M. Andersen, A. E. Warrington, P. A. Decker, T. J.** 40 D. Hoplin, S. Ikram, A. B. Zubair, K. M. Andersen, A. E. Warrington, P. A. Decker, T. J.
41 Kaufmann, J. L. Campian, J. E. Eckel-Passow, S. H. Kizilbash, S. Tortorelli, T. C. Burns 41 Kaufmann, J. L. Campian, J. E. Eckel-Passow, S. H. Kizilbash, S. Tortorelli, T. C. Burns,
42 Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant 42 Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant
43 gliomas. Neuro-Oncology Advances 5, (2023). ⁴³gliomas. *Neuro-Oncology Advances* **⁵**, (2023). 44 28. Y. Fujita, L. Nunez-Rubiano, A. Dono, A. Bellman, M. Shah, J. C. Rodriguez, V. Putluri, 45 (A. H. M. Kamal, N. Putluri, R. F. Riascos, J. J. Zhu, Y. Esquenazi, L. Y. Ballester, IDH1 45 A. H. M. Kamal, N. Putluri, R. F. Riascos, J. J. Zhu, Y. Esquenazi, L. Y. Ballester, IDH1
46 p. R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-46 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-
47 mutant gliomas. J Neurooncol **159**, 261-270 (2022). ⁴⁷mutant gliomas. *J Neurooncol* **¹⁵⁹**, 261-270 (2022). 48 29. L. Y. Ballester, G. Lu, S. Zorofchian, V. Vantaku, V. Putluri, Y. Yan, O. Arevalo, P. Zhu, 49
49 R. F. Riascos, A. Sreekumar, Y. Esquenazi, N. Putluri, J.-J. Zhu, Analysis of 49 R. F. Riascos, A. Sreekumar, Y. Esquenazi, N. Putluri, J.-J. Zhu, Analysis of
50 cerebrospinal fluid metabolites in patients with primary or metastatic central r 50 cerebrospinal fluid metabolites in patients with primary or metastatic central nervous
51 system tumors. Acta Neuropathologica Communications 6, 85 (2018). ⁵¹system tumors. *Acta Neuropathologica Communications* **⁶**, 85 (2018).

1 30. J. Kalinina, J. Ahn, N. S. Devi, L. Wang, Y. Li, J. J. Olson, M. Glantz, T. Smith, E. L. Kim, 3
2 A. Giese, R. L. Jensen, C. C. Chen, B. S. Carter, H. Mao, M. He, E. G. Van Meir, 2 A. Giese, R. L. Jensen, C. C. Chen, B. S. Carter, H. Mao, M. He, E. G. Van Meir,
3 Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glior 3 Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma
4 Patients with Mutated Isocitrate Dehydrogenase. Clin Cancer Res 22, 6256-6265 (20 4 Patients with Mutated Isocitrate Dehydrogenase. *Clin Cancer Res* 22, 6256-6265 (2016).
5 31. J. Kalinina, J. Peng, J. C. Ritchie, E. G. Van Meir, Proteomics of gliomas: initial 5 31. J. Kalinina, J. Peng, J. C. Ritchie, E. G. Van Meir, Proteomics of gliomas: initial
6 biomarker discovery and evolution of technology. Neuro Oncol 13, 926-942 (20 ⁶biomarker discovery and evolution of technology. *Neuro Oncol* **¹³**, 926-942 (2011). 7 32. M. U. Schuhmann, H. D. Zucht, R. Nassimi, G. Heine, C. G. Schneekloth, H. J.
8 Stuerenburg, H. Selle, Peptide screening of cerebrospinal fluid in patients with 8 Stuerenburg, H. Selle, Peptide screening of cerebrospinal fluid in patients with
9 glioblastoma multiforme. Eur J Surg Oncol 36, 201-207 (2010). ⁹glioblastoma multiforme. *Eur J Surg Oncol* **³⁶**, 201-207 (2010). 10 33. D. Schmid, U. Warnken, P. Latzer, D. C. Hoffmann, J. Roth, S. Kutschmann, H.
11 Saschonek, P. Rübmann, M. Foltyn, P. Vollmuth, F. Winkler, C. Seliger, M. Felix 11 Jaschonek, P. Rübmann, M. Foltyn, P. Vollmuth, F. Winkler, C. Seliger, M. Felix, F.
12 Sahm, J. Haas, D. Reuss, M. Bendszus, B. Wildemann, A. von Deimling, W. Wick, 1 12 Sahm, J. Haas, D. Reuss, M. Bendszus, B. Wildemann, A. von Deimling, W. Wick, T.
13 Kessler, Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid 13 Kessler, Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in
14 patients with brain malignancies. J Neurochem **158**, 522-538 (2021). 14 patients with brain malignancies. *J Neurochem* **158**, 522-538 (2021).
15 34. F. W. Khwaja, M. S. Reed, J. J. Olson, B. J. Schmotzer, G. Y. Gillesp 15 34. F. W. Khwaja, M. S. Reed, J. J. Olson, B. J. Schmotzer, G. Y. Gillespie, A. Guha, M. D.
16 **Changer, S. Kesari, J. Pohl, E. G. Van Meir, Proteomic identification of biomarkers in the** 16 Groves, S. Kesari, J. Pohl, E. G. Van Meir, Proteomic identification of biomarkers in the
17 cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 6, 559-570 (2007). 17 cerebrospinal fluid (CSF) of astrocytoma patients. *J Proteome Res* 6, 559-570 (2007).
18 35. F. W. Khwaia, J. S. Duke-Cohan, D. J. Brat, E. G. Van Meir, Attractin is elevated in the 18 35. F. W. Khwaja, J. S. Duke-Cohan, D. J. Brat, E. G. Van Meir, Attractin is elevated in the
19 cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell 19 cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell
20 migration. Clin Cancer Res 12, 6331-6336 (2006). ²⁰migration. *Clin Cancer Res* **¹²**, 6331-6336 (2006). ²¹36. N. Mikolajewicz, S. Khan, M. Trifoi, A. Skakdoub, V. Ignatchenko, S. Mansouri, J. 22 Zuccato, B. E. Zacharia, M. Glantz, G. Zadeh, J. Moffat, T. Kislinger, A. Mansouri,
23 Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance 23 Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of 24 containmalignancies. Neuro-Oncology Advances 4, (2022). ²⁴brain malignancies. *Neuro-Oncology Advances* **⁴**, (2022). 25 37. N. Rostgaard, M. H. Olsen, M. Ottenheijm, L. Drici, A. H. Simonsen, P. Plomgaard, H.
26 **Canadar Barat, H. H. Poulsen, H. Zetterberg, K. Blennow, S. G. Hasselbalch, N. MacAulay, M.** 26 Gredal, H. H. Poulsen, H. Zetterberg, K. Blennow, S. G. Hasselbalch, N. MacAulay, M.
27 Subler, Differential proteomic profile of lumbar and ventricular cerebrospinal fluid. Fluids 27 Juhler, Differential proteomic profile of lumbar and ventricular cerebrospinal fluid. *Fluids* 28 *Barriers CNS* 20, 6 (2023). ²⁸*Barriers CNS* **²⁰**, 6 (2023). 29 38. Y. Kim, J. Jeon, S. Mejia, C. Q. Yao, V. Ignatchenko, J. O. Nyalwidhe, A. O. Gramolini, 20
30 **R. S. Lance, D. A. Troyer, R. R. Drake, P. C. Boutros, O. J. Semmes, T. Kislinger,** 30 R. S. Lance, D. A. Troyer, R. R. Drake, P. C. Boutros, O. J. Semmes, T. Kislinger, 31 Cargeted proteomics identifies liquid-biopsy signatures for extracapsular prostate 31 Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate
32 cancer. Nat Commun 7, 11906 (2016). 32 cancer. *Nat Commun* **7**, 11906 (2016).
33 39. U. Kuzmanov, N. Musrap, H. Kosanam 33 39. U. Kuzmanov, N. Musrap, H. Kosanam, C. R. Smith, I. Batruch, A. Dimitromanolakis, E.
34 **P. Diamandis, Glycoproteomic identification of potential glycoprotein biomarkers in** 34 P. Diamandis, Glycoproteomic identification of potential glycoprotein biomarkers in
35 ovarian cancer proximal fluids. *Clin Chem Lab Med* 51, 1467-1476 (2013). ovarian cancer proximal fluids. *Clin Chem Lab Med* 51, 1467-1476 (2013).
36 december, D. Ayers, J. Bertino, C. Bock, A. Bock, E. N. Brody, J. Carter, A. B 36 40. L. Gold, D. Ayers, J. Bertino, C. Bock, A. Bock, E. N. Brody, J. Carter, A. B. Dalby, B. E.
37 **Eaton, T. Fitzwater, D. Flather, A. Forbes, T. Foreman, C. Fowler, B. Gawande, M.** 37 Eaton, T. Fitzwater, D. Flather, A. Forbes, T. Foreman, C. Fowler, B. Gawande, M.
38 Goss, M. Gunn, S. Gupta, D. Halladay, J. Heil, J. Heilig, B. Hicke, G. Husar, N. Jan 38 Goss, M. Gunn, S. Gupta, D. Halladay, J. Heil, J. Heilig, B. Hicke, G. Husar, N. Janjic, T.
39 Jarvis, S. Jennings, E. Katilius, T. R. Keeney, N. Kim, T. H. Koch, S. Kraemer, L. Kroiss, 39 Jarvis, S. Jennings, E. Katilius, T. R. Keeney, N. Kim, T. H. Koch, S. Kraemer, L. Kroiss, 30
40 N. Le, D. Levine, W. Lindsey, B. Lollo, W. Mayfield, M. Mehan, R. Mehler, S. K. Nelson, 40 N. Le, D. Levine, W. Lindsey, B. Lollo, W. Mayfield, M. Mehan, R. Mehler, S. K. Nelson,
41 M. Nelson, D. Nieuwlandt, M. Nikrad, U. Ochsner, R. M. Ostroff, M. Otis, T. Parker, S. 41 M. Nelson, D. Nieuwlandt, M. Nikrad, U. Ochsner, R. M. Ostroff, M. Otis, T. Parker, S.
42 Pietrasiewicz, D. I. Resnicow, J. Rohloff, G. Sanders, S. Sattin, D. Schneider, B. Singe 42 Pietrasiewicz, D. I. Resnicow, J. Rohloff, G. Sanders, S. Sattin, D. Schneider, B. Singer, 43 (M. Stanton, A. Sterkel, A. Stewart, S. Stratford, J. D. Vaught, M. Vrkljan, J. J. Walker, M. 43 M. Stanton, A. Sterkel, A. Stewart, S. Stratford, J. D. Vaught, M. Vrkljan, J. J. Walker, M.
44 Watrobka, S. Waugh, A. Weiss, S. K. Wilcox, A. Wolfson, S. K. Wolk, C. Zhang, D. Zichi, 44 Watrobka, S. Waugh, A. Weiss, S. K. Wilcox, A. Wolfson, S. K. Wolk, C. Zhang, D. Zichi,
45 Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* 5, ⁴⁵Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* **⁵**, 46 e15004 (2010).
47 41. J. C. Rohloff, A. 47 41. J. C. Rohloff, A. D. Gelinas, T. C. Jarvis, U. A. Ochsner, D. J. Schneider, L. Gold, N.
48 Janjic, Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and T 48 Janjic, Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their
49 Julie as Diagnostic and Therapeutic Agents. Molecular Therapy - Nucleic Acids 3, e201 ⁴⁹Use as Diagnostic and Therapeutic Agents. *Molecular Therapy - Nucleic Acids* **³**, e201 $(2014).$

1 42. P. Halleux, S. Schurmans, S. N. Schiffman, R. Lecocq, J. L. Conreur, J. Dumont, J. J.
2 Vanderhaeghen, Calcium binding protein calcyphosine in dog central astrocytes and 2 Vanderhaeghen, Calcium binding protein calcyphosine in dog central astrocytes and
3 ependymal cells and in peripheral neurons. J Chem Neuroanat 15, 239-250 (1998). ³ependymal cells and in peripheral neurons. *J Chem Neuroanat* **¹⁵**, 239-250 (1998). 4 43. V. Ribes, J. Briscoe, Establishing and interpreting graded Sonic Hedgehog signaling
5 during vertebrate neural tube patterning: the role of negative feedback. Cold Spring F ⁵during vertebrate neural tube patterning: the role of negative feedback. *Cold Spring Harb* ⁶*Perspect Biol* **¹**, a002014 (2009). 7 44. C. Riviere-Cazaux, L. P. Carlstrom, K. Rajani, A. Munoz-Casabella, M. Rahman, A.
8 Gharibi-Loron, D. A. Brown, K. J. Miller, J. J. White, B. T. Himes, I. Jusue-Torres, S. 8 Gharibi-Loron, D. A. Brown, K. J. Miller, J. J. White, B. T. Himes, I. Jusue-Torres, S.
9 Ikram, S. C. Ransom, R. Hirte, J.-H. Oh, W. F. Elmquist, J. N. Sarkaria, R. A. Vaubel 9 Ikram, S. C. Ransom, R. Hirte, J.-H. Oh, W. F. Elmquist, J. N. Sarkaria, R. A. Vaubel, M.
10 Rodriguez, A. E. Warrington, S. H. Kizilbash, T. C. Burns, Blood-brain barrier disruption 10 Rodriguez, A. E. Warrington, S. H. Kizilbash, T. C. Burns, Blood-brain barrier disruption
11 defines the extracellular metabolome of live human high-grade gliomas. 11 defines the extracellular metabolome of live human high-grade gliomas.
12 Communications Biology 6, 653 (2023). ¹²*Communications Biology* **⁶**, 653 (2023). 13 45. A. T. Argaw, B. T. Gurfein, Y. Zhang, A. Zameer, G. R. John, VEGF-mediated disruption
14 feral of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A 14 of endothelial CLN-5 promotes blood-brain barrier breakdown. *Proc Natl Acad Sci U S A*
15 **106**, 1977-1982 (2009). ¹⁵**106**, 1977-1982 (2009). 16 46. M. R. Gilbert, J. J. Dignam, T. S. Armstrong, J. S. Wefel, D. T. Blumenthal, M. A.
17 September 17, Colman, A. Chakravarti, S. Pugh, M. Won, R. Jeraj, P. D. Brown, 17 Vogelbaum, H. Colman, A. Chakravarti, S. Pugh, M. Won, R. Jeraj, P. D. Brown, K. A.
18 Jaeckle, D. Schiff, V. W. Stieber, D. G. Brachman, M. Werner-Wasik, I. W. Tremont-18 Jaeckle, D. Schiff, V. W. Stieber, D. G. Brachman, M. Werner-Wasik, I. W. Tremont-¹⁹Lukats, E. P. Sulman, K. D. Aldape, W. J. Curran, M. P. Mehta, A Randomized Trial of ²⁰Bevacizumab for Newly Diagnosed Glioblastoma. *New England Journal of Medicine* ²¹**370**, 699-708 (2014). 22 47. R. Radu, G. E. D. Petrescu, R. M. Gorgan, F. M. Brehar, GFAPδ: A Promising
23 Biomarker and Therapeutic Target in Glioblastoma. *Front Oncol* **12**, 859247 (2 ²³Biomarker and Therapeutic Target in Glioblastoma. *Front Oncol* **¹²**, 859247 (2022). 24 48. C. S. Jung, C. Foerch, A. Schänzer, A. Heck, K. H. Plate, V. Seifert, H. Steinmetz, A.
25 Raabe, M. Sitzer, Serum GFAP is a diagnostic marker for glioblastoma multiforme. Br ²⁵Raabe, M. Sitzer, Serum GFAP is a diagnostic marker for glioblastoma multiforme. *Brain* ²⁶**130**, 3336-3341 (2007). 49. J. Gállego Pérez-Larraya, S. Paris, A. Idbaih, C. Dehais, F. Laigle-Donadey, S. Navarro,
28 L. Capelle, K. Mokhtari, Y. Marie, M. Sanson, Diagnostic and prognostic value of
29 preoperative combined GFAP, IGFBP-2, and Y 28 L. Capelle, K. Mokhtari, Y. Marie, M. Sanson, Diagnostic and prognostic value of
29 preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients wi 29 preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with
30 **produkt onling and Cancer 120**, 3972-3980 (2014). preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with
30. M. Osada, H. L. Park, M. J. Park, J. W. Liu, G. Wu, B. Trink, D. Sidransky, A p53-type
32. September 1988 and the GDF15 promoter confers hi ³⁰glioblastoma. *Cancer* **¹²⁰**, 3972-3980 (2014). 32 response element in the GDF15 promoter confers high specificity for p53 activation.
33 Biochem Biophys Res Commun 354, 913-918 (2007). ³³*Biochem Biophys Res Commun* **³⁵⁴**, 913-918 (2007). ³⁴51. M. V. Goldberg, C. G. Drake, LAG-3 in Cancer Immunotherapy. *Curr Top Microbiol* ³⁵*Immunol* **³⁴⁴**, 269-278 (2011). 36 52. K. Singh, K. M. Hotchkiss, I. F. Parney, J. De Groot, S. Sahebjam, N. Sanai, M. Platten, 37
37 **E. Galanis, M. Lim, P. Y. Wen, G. Minniti, H. Colman, T. F. Cloughesy, M. P. Mehta, M.** 57 E. Galanis, M. Lim, P. Y. Wen, G. Minniti, H. Colman, T. F. Cloughesy, M. P. Mehta, M.
38 Geurts, I. Arrillaga-Romany, A. Desjardins, K. Tanner, S. Short, D. Arons, E. Duke, W. 38 Geurts, I. Arrillaga-Romany, A. Desjardins, K. Tanner, S. Short, D. Arons, E. Duke, W.
39 Geurts, S. J. Bagley, D. M. Ashley, P. Kumthekar, R. Verhaak, A. J. Chalmers, A. P. Pate 39 Wick, S. J. Bagley, D. M. Ashley, P. Kumthekar, R. Verhaak, A. J. Chalmers, A. P. Patel,
40 C. Watts, P. E. Fecci, T. T. Batchelor, M. Weller, M. A. Vogelbaum, M. Preusser, M. S. 40 C. Watts, P. E. Fecci, T. T. Batchelor, M. Weller, M. A. Vogelbaum, M. Preusser, M. S.
41 Serger, M. Khasraw, Correcting the drug development paradigm for glioblastoma 41 Berger, M. Khasraw, Correcting the drug development paradigm for glioblastoma
42 requires serial tissue sampling. Nature Medicine 29, 2402-2405 (2023). fequires serial tissue sampling. *Nature Medicine* **29**, 2402-2405 (2023).
43 53. H. Chen, J. Ji, L. Zhang, T. Chen, Y. Zhang, F. Zhang, J. Wang, Y. Ke, 43 53. H. Chen, J. Ji, L. Zhang, T. Chen, Y. Zhang, F. Zhang, J. Wang, Y. Ke, Inflammatory
44 fesponsive neutrophil-like membrane-based drug delivery system for post-surgical 44 responsive neutrophil-like membrane-based drug delivery system for post-surgical
45 glioblastoma therapy. J Control Release **362**, 479-488 (2023). ⁴⁵glioblastoma therapy. *J Control Release* **³⁶²**, 479-488 (2023). 46 54. A. M. Knudsen, B. Halle, O. Cédile, M. Burton, C. Baun, H. Thisgaard, A. Anand, C.
47 Hubert, M. Thomassen, S. R. Michaelsen, B. B. Olsen, R. H. Dahlrot, R. Bjerkvig, J. 47 Hubert, M. Thomassen, S. R. Michaelsen, B. B. Olsen, R. H. Dahlrot, R. Bjerkvig, J. D.
48 Lathia, B. W. Kristensen, Surgical resection of glioblastomas induces pleiotrophin-48 Lathia, B. W. Kristensen, Surgical resection of glioblastomas induces pleiotrophin-
49 mediated self-renewal of glioblastoma stem cells in recurrent tumors. Neuro Oncol ⁴⁹mediated self-renewal of glioblastoma stem cells in recurrent tumors. *Neuro Oncol* **²⁴**, ⁵⁰1074-1087 (2022).

- 155. E. Aasebø, J. A. Opsahl, Y. Bjørlykke, K. M. Myhr, A. C. Kroksveen, F. S. Berven, 2
2 Effects of blood contamination and the rostro-caudal gradient on the human Effects of blood contamination and the rostro-caudal gradient on the human
3 cerebrospinal fluid proteome. PLoS One 9, e90429 (2014). ³cerebrospinal fluid proteome. *PLoS One* **⁹**, e90429 (2014). ⁴56. G. H. Sato, The role of serum in cell culture. *Biochemical actions of hormones* **³**, 391- ⁵396 (1975). 6 57. Y. Wang, S. Springer, M. Zhang, K. W. McMahon, I. Kinde, L. Dobbyn, J. Ptak, H. Brem,
7 K. Chaichana, G. L. Gallia, Z. L. Gokaslan, M. L. Groves, G. I. Jallo, M. Lim, A. Olivi, A. 7 K. Chaichana, G. L. Gallia, Z. L. Gokaslan, M. L. Groves, G. I. Jallo, M. Lim, A. Olivi, A.
8 Cuinones-Hinojosa, D. Rigamonti, G. J. Riggins, D. M. Sciubba, J. D. Weingart, J.-P. 8 Quinones-Hinojosa, D. Rigamonti, G. J. Riggins, D. M. Sciubba, J. D. Weingart, J.-P.
9 Wolinsky, X. Ye, S. M. Oba-Shinjo, S. K. N. Marie, M. Holdhoff, N. Agrawal, L. A. Diaz 9 Wolinsky, X. Ye, S. M. Oba-Shinjo, S. K. N. Marie, M. Holdhoff, N. Agrawal, L. A. Diaz,
10 N. Papadopoulos, K. W. Kinzler, B. Vogelstein, C. Bettegowda, Detection of tumor-10 N. Papadopoulos, K. W. Kinzler, B. Vogelstein, C. Bettegowda, Detection of tumor-
11 derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and s 11 derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal
12 cord. Proceedings of the National Academy of Sciences **112**, 9704-9709 (2015). 12 cord. *Proceedings of the National Academy of Sciences* **112**, 9704-9709 (2015).
13 58. L. S. Graham, C. C. Pritchard, M. T. Schweizer, Hypermutation, Mismatch Repai 13 58. L. S. Graham, C. C. Pritchard, M. T. Schweizer, Hypermutation, Mismatch Repair
14 **Deficiency, and Defining Predictors of Response to Checkpoint Blockade.** Clin Ca. 14 Deficiency, and Defining Predictors of Response to Checkpoint Blockade. *Clin Cancer* 15 **Res 27**, 6662-6665 (2021). ¹⁵*Res* **²⁷**, 6662-6665 (2021). 16 59. S. Harris-Bookman, D. Mathios, A. M. Martin, Y. Xia, E. Kim, H. Xu, Z. Belcaid, M.
17 **Polanczyk, T. Barberi, D. Theodros, J. Kim, J. M. Taube, P. C. Burger, M. Selby, C** 17 Polanczyk, T. Barberi, D. Theodros, J. Kim, J. M. Taube, P. C. Burger, M. Selby, C.
18 Taitt, A. Korman, X. Ye, C. G. Drake, H. Brem, D. M. Pardoll, M. Lim, Expression of 18 Taitt, A. Korman, X. Ye, C. G. Drake, H. Brem, D. M. Pardoll, M. Lim, Expression of
19 **LAG-3** and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclo 19 LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal
20 http://www.india.com/2008/2018/2018.html 20 antibodies in glioblastoma. *Int J Cancer* **143**, 3201-3208 (2018).
21 60. J. Timsina, D. Gomez-Fonseca, L. Wang, A. Do, D. Western, I. *I* 2160. J. Timsina, D. Gomez-Fonseca, L. Wang, A. Do, D. Western, I. Alvarez, M. Aguilar, P.
22 **Cambush Pastor, R. L. Henson, E. Herries, C. Xiong, S. E. Schindler, A. M. Fagan, R. J. Batema** 22 Pastor, R. L. Henson, E. Herries, C. Xiong, S. E. Schindler, A. M. Fagan, R. J. Bateman,
23 M. Farlow, J. C. Morris, R. J. Perrin, K. Moulder, J. Hassenstab, J. Vöglein, J. Chhatwal, 23 M. Farlow, J. C. Morris, R. J. Perrin, K. Moulder, J. Hassenstab, J. Vöglein, J. Chhatwal, 24 (1994).
24 H. Mori, Y. J. Sung, C. Cruchaga, Comparative Analysis of Alzheimer's Disease 24 H. Mori, Y. J. Sung, C. Cruchaga, Comparative Analysis of Alzheimer's Disease
25 Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform 25 Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and
26 **Communicassay-Based Approach**. J Alzheimers Dis 89, 193-207 (2022). ²⁶Immunoassay-Based Approach. *J Alzheimers Dis* **⁸⁹**, 193-207 (2022). 27 61. M. D. Robinson, A. Oshlack, A scaling normalization method for differential expression
28 analysis of RNA-seq data. Genome biology 11, 1-9 (2010). ²⁸analysis of RNA-seq data. *Genome biology* **¹¹**, 1-9 (2010).
-

¹**ACKNOWLEDGMENTS**

²We thank our patients and their families for their participation in this study. We thank the Mayo ³Clinic Neurosurgery Clinical Research, neurosurgical residents, and operating staff for their 4 technical and research support.

Funding: CRC was supported by the National Institute of Health T32GM145408. TCB, JLC, and IFP were supported by the Ivy Foundation. IFP was also supported by NCI U19 CA2643632 and an MISP grant from Merck Pharmaceuticals. TCB and SHK were supported by NINDS R61 NS122096. TCB was also supported by Mayo Clinic Center for Individualized Medicine and CCaTS award UL1TR002377, the American Brain Tumor Association, Brains Together for the 10 Cure, Humor to fight the Tumor, and Lucius & Terrie McKelvey.

¹¹**Author contributions:**

- 12 Conceptualization: CRC, TCB, LPC
- 13 Sample acquisition and processing: CRC, AEW, MDH, KMA, NM, SI, KG, BTH, IJT,
- 14 JJV, IFP, TCB
- 15 Data analysis: CRC, CJG, SD, TCB
- 16 Protocol and project administration: CRC, LPC, AMC, MDH, EAP, TCB
- 17 Supervision: TCB, AEW
- ¹⁸Writing original draft: CRC, TCB
- ¹⁹Writing review & editing: all authors

²⁰**Competing interests:** F.M. is a cofounder of and has equity in Harbinger Health, has equity in

- 21 Zephyr AI, and consults for Harbinger Health and Zephyr AI. She is on the board of directors of
- 22 Exscientia Plc. She declares that none of these relationships are directly or indirectly related to
- 23 the content of this manuscript.
- ²⁴**Data and materials availability:** All data are available as supplementary files.

- ¹**Ethics:** This study was approved by the Mayo Clinic Institutional Review Board and all 2 participants provided their consent to participate in this study. This study was performed in
- 3 accordance with the Declaration of Helsinki.
- ⁴**Consent:** All participants have provided consent for publication.

-
- -
7 7
-

¹**FIGURE LEGENDS**

²**Figure 1. The CSF proteome differs by anatomical location.**

180 265 257 136 170 284 101 123 225 162 233 300 245 288 265 123 170 245 257 233 225 288 180 136 101 284 162 300 Intracranial location V= ventricle SA= subarachnoid SA SA SA SA SA V V V R R SA V R R R= resection cavity

¹**1A.** (i) A volcano plot was generated by performing a series of Mann-Whitney U-tests with 2 Benjamini-Hochberg correction on GBM CSF samples obtained from the ventricular system 3 (n=20) versus the subarachnoid space (n=23). Cut-offs were FC>1.5 and adjusted p-⁴value<0.05. (ii-iii) The ventricular and subarachnoid CSF samples were each split in half into 5 discovery and validation cohorts ($n=10$ each in discovery and validation for ventricular; $n=12$ in ⁶discovery and n=11 in ventricular for the validation cohort), with subarachnoid versus ventricular ⁷CSF ranked fold-change lists generated for both cohorts. Enrichment analysis was performed to ⁸evaluate the enrichment of the discovery subarachnoid versus ventricular ranked fold-change 9 list for the (ii) validation subarachnoid and (iii) validation ventricular CSF proteomes (top 350 10 proteins based on fold-change).

¹¹**1B.** (i) A volcano plot was generated by performing a series of Wilcoxon-Signed rank tests with 12 Benjamini-Hochberg correction on paired intracranial and lumbar CSF samples from patients 13 with gliomas (n=14). (ii-iii) The lumbar and intracranial pairs were split in half into discovery and 14 validation cohorts (n=7 pairs in each group), with paired intracranial versus lumbar ranked fold-15 change lists generated for both cohorts. Enrichment analysis was performed to evaluate the 16 enrichment of the discovery intracranial versus lumbar ranked fold-change list for the (ii) 17 validation intracranial and (ii) validation lumbar CSF proteomes. (iv) Hierarchical clustering was 18 performed on the paired lumbar and intracranial CSF samples using the top 5% (350) proteins 19 via t-test. (v) Ranked average fold-change lists were generated using the paired intracranial 20 versus lumbar patient samples based on anatomical location (ventricle, subarachnoid, or 21 resection cavity). Enrichment analysis was performed to evaluate the enrichment of each 22 ranked list for proteomic libraries consisting of the top 5% (350 proteins) from the average 23 paired intracranial versus LP lists. All FDR=0.000.

²⁴**Figure 2**. **Glioma resection impacts the CSF proteome at early and delayed timepoints.**

1 **2A.** (i) Ranked fold-change lists were generated from each patient's paired pre-versus-post-²early resection (POD<35) CSF samples (n=20). Ranked protein order is shown as a heatmap ³from 1 (higher pre-resection; red) to 7,011 (higher early post-resection; purple). The average 4 rank across all 20 patients was used to list proteins. The top and bottom 200 proteins are 5 shown. (ii) The 20 pre-versus-early post-resection CSF pairs were split in half into discovery and ⁶validation cohorts based on sequential order. Enrichment analysis of the discovery post- versus ⁷pre-early resection ranked fold-change list was performed for the validation pre-resection CSF 8 proteome. (iii). A volcano plot was generated by performing a series of Wilcoxon Signed-Rank 9 tests with Benjamini-Hochberg correction on the paired pre-versus- early post-resection CSF 10 samples (n=20). Cut-offs were FC>1.5 and adjusted p-value<0.05. (iv) Functional protein 11 network analysis was performed via STRING.db on the top 200 proteins significantly elevated 12 prior to versus early after resection based on FC in 3Aiii. Gene ontology (GO) processes and 13 their FDRs are reported.

¹⁴**2B**. Similar analyses were performed to 3A for the paired early-versus-delayed post-resection ¹⁵CSF samples (n=9 pairs). For (ii), the discovery cohort had 5 pairs of samples while the 16 validation cohort had 4 pairs, based on sequential patient number.

¹⁷**2C**. Similar analyses were again performed to 3A-B, using the pre-resection versus delayed 18 post-resection CSF samples ($n=11$ pairs). For (iii), the discovery cohort had 6 pairs of samples, 19 while the validation cohort had 5 pairs, based on sequential patient order.

²⁰**Figure 3. The impact of resection evolves over time and is detectable at recurrence.**

3A. (i) The abundance of the top 10 proteins unique to each timepoint are shown for 9 patients 2 with gliomas who had CSF samples acquired intra-operatively, early post-resection (POD<35), and delayed post-resection (POD>70). Proteins unique to each timepoint were found by identifying the proteins that were significantly elevated (FC>1.5, adjusted p<0.05) at that 5 timepoint when compared to both of the other timepoints. The fold-change in bloody versus clean CSF samples (n=7 pairs) is also shown. (ii) The abundance of the top 10 plasma-associated proteins are shown for these patients' samples.

3B. The abundance at each timepoint for each patient is shown for (i) Fibroblast growth factor 1 (FGF1), (ii) Histone 2B Type 3-B (H2BU1), and (iii) growth differentiation factor 15 (GDF-15), which were in the top 10 proteins at the pre-resection, early post-resection, and delayed post-11 resection timepoints, respectively.

¹²**3C**. (i) Proteins were identified that were significantly elevated in both the early and delayed 13 post-resection timepoints when each were compared to the pre-resection timepoint (FC>1.5 and 14 adjusted p<0.05). 150 proteins overlapped between these two comparisons. Enrichment 15 analysis was performed to evaluate the enrichment of the recurrent versus primary GBM 16 proteome ranked list for these 150 proteins that were elevated at both early and delayed post-17 resection timepoints as compared to pre-resection. (ii-iii) Chitotriosidase 1 (CHIT1) was 18 evaluated in the pre-resection, early post-resection, and delayed post-resection timepoints, as 19 well as in primary (n=31) versus recurrent (n=21) GBM samples acquired intra-operatively.

²⁰**Figure 4. Intracranial CSF can be acquired longitudinally for evaluation of candidate** ²¹**monitoring biomarkers and pharmacodynamic impact of therapies.**

²**4A**. BCAN, epidermal growth factor receptor (EGFR), growth differentiation factor-15 (GDF-15), ³VEGFA-A, and GFAP were evaluated in intracranial CSF from patient 24, who had a recurrent ⁴GBM with known EGFR amplification. Green box = days on CCNU; maroon box = days on 5 bevacizumab.

4B. The normalized RFUs of brevican (BCAN), glial fibrillary acidic protein (GFAP), and vascular endothelial growth factor-A (VEGF-A) were evaluated over time in longitudinal intracranial CSF obtained from a patient with an astrocytoma, IDH-mutant, grade 4 via an Ommaya reservoir. D-2-hydroxyglutarate (D-2-HG) was also evaluated at each timepoint. Red 10 box = days during which patient underwent chemoradiation; yellow box = days on adjuvant 11 temozolomide (adj. TMZ).

¹²**4C**. BCAN, GFAP, and VEGF-A were evaluated in longitudinal intracranial CSF from a patient 13 with an astrocytoma, IDH-mutant, grade 4, as well as D-2-HG. Additionally, the T1-post ¹⁴gadolinium positive (T1+Gad) volume was calculated from MRIs obtained at each timepoint.

- ¹Red box = days during which patient underwent chemoradiation; yellow box = days on adjuvant
- 2 temozolomide (adj. TMZ).
- ³**4D**. The top 10 proteins based on fold-change are shown for post-versus-pre-treatment with (i)
- ⁴bevacizumab in patient 24 from 4A, as well as (ii) post-versus-pre-pembrolizumab in patient 79,
- 5 who had a GBM with a hypermutated phenotype.

1 Table 1. The Impact of Anatomical location and resecti